Conference Roundup

Liquid Biopsy Can Guide Treatment in Bladder Cancer

Posted on

A liquid biopsy biomarker may act as a guide when determining treatment between radical cystectomy and bladder preservation in muscle-invasive bladder cancer (MIBC, according to a presentation by David T. Miyamoto, MD, PhD at the 2020 American Society of Clinical Oncology Genitourinary Cancers Symposium.

Although this non-invasive test can be performed repeatedly, obtaining enough circulating tumor cells for use can be difficult, he said.

Dr Miyamoto discussed findings from a large meta-analysis including 1339 patients from 20 studies. Circulating tumor cells were detectable in 20%-30% of patients with non-metastatic bladder cancer versus 40%-100% of patients with metastatic bladder cancer. Circulating tumor cells were significantly associated with stage 3 or stage 4 cancers (OR 4.6, 95% CI 2.3-9.0).


Miyamoto DR. 2020 ASCO Genitourinary Cancers Symposium (#GU20), February 13th-February 15th, San Francisco, CA.

Zhang Z, Fan W, Deng Q, et al. The prognostic and diagnostic value of circulating tumor cells in bladder cancer and upper tract urothelial carcinoma: a meta-analysis of 30 published studies. Oncotarget 2017; 8(35).

Related Articles
Potential Therapy for Rare Neurologic Disease
Apr 06, 2020
US FDA Grants Orphan Drug Designation for Retrotope’s RT001 in the Treatment of Progressive SupraNuclear Palsy (PSP)
Mar 16, 2020
TG Therapeutics Announces Data Presentations at the Upcoming American Academy of Neurology 72nd Annual Meeting
Mar 11, 2020